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icy can be implemented only if decision-makers have the access to analytical tools
to address different policy scenarios. It requires initial investment, which pays off
in better decisions.
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OBJECTIVES: The aim of the current study is to utilize two different methodologies
to estimate the prevalence and burden of type 2 diabetes (T2D) and obesity among
the adult population in France. METHODS: Two separate representative data
sources were used for the adult French population. Data from the French respon-
dents of the EU National Health and Wellness Survey (NHWS) (N15,051) and the
OBEPI survey (N25,286) were used. The NHWS is an internet-based annual survey
and the OBEPI is a mailed survey conducted every three years, validated by the
French authorities. Prevalence information for T2D, comorbid treatments, and BMI
were analyzed using both data sources. The humanistic and economic burden of
T2D was analyzed only from the NHWS data. RESULTS: From NHWS, 44.3% of
respondents from France were male and the average age was 45.1 years (SD15.5).
From OBEPI, 47.8% were male and the average age was 48.2 years (SD17.8). A total
of 30.5% (OBEPI31.9%) and 15.6% (OBEPI14.5%) of the French population were
estimated to be overweight and obese, respectively. A total of 4.4% (from NHWS)
and 4.8% (from OBEPI) of the adult French population reported suffering from T2D.
Among these patients, 15.1% and 80.5% were taking an insulin and oral treatment,
respectively (12.4% by OHAinsulin and 76.0% by OHA only as estimated by OBEPI).
From NHWS, a significant burden was observed among patients with T2D as they
reported significantly lower levels physical quality of life (using the SF-12v2; 42.6
vs. 50.1, p.05) and significantly greater work impairment (26.7% vs. 18.2%, p.05)
and physician visits (8.7 vs. 5.5, p.05). CONCLUSIONS: Both internet and mailed
survey methodologies provided consistent prevalence estimates of diabetes and
obesity among the French population. Further, despite the high prevalence of treat-
ment, significant effects are observed on health outcomes among T2D patients,
highlighting the unmet need.
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OBJECTIVES: According to DATASUS, from 1996 to 2005, there were more than 1
million hospitalizations related to smoking, with total costs sum of half billion
dollars. The aim of this study was to assess the cost-effectiveness of varenicline
compared to other existing strategies for smoking cessation in an adult population
cohort from the public payer’s perspective. METHODS: The Benefits of Smoking
Cessation on Outcomes (BENESCO) simulation model was used for an 18 years of
age and older cohort of 557,881 smokers, within a lifetime time horizon. Smoking
cessation therapies in comparison were: varenicline (0.5–2 mg/day), bupropion (300
mg/day), nicotine replacement therapy (NRT) (5-10 mg/day), and unaided cessa-
tion. Relapse rates were considered as 6.3% for the first 5 years after cessation, 2%
for years 6 to 10 and 1% for subsequent years. Effectiveness measure was Life-Year
gained (LYG). Smoking and smoking-related heath condition’s prevalence, re-
source use and costs data were obtained from DATASUS, INCA (National Cancer
Institute), INCOR (Heart Institute) and DECIT (Science and Technology Department
of Brazil). The model used a 5% discount rate for health outcomes and costs were
expressed in 2010 USD. RESULTS: LYG for varenicline was 7310 compared to 7295
from bupropion, 7294 from nicotine replacement therapy and 7273 for untreated
treatment. Compared to untreated patients, varenicline reduced smoking-related
morbidity by 10,757 events, prevented 8,612 early deaths due to smoking related
events, representing savings for US$139.602.241,20 from heathcare expenses. The
net average cost per additional quitter showed that varenicline was cost-saving
against bupropion (- USD 1.122,00) and nicotine replacement therapy (- US$
46.184,40). CONCLUSIONS: Smoking cessation therapy with varenicline is cost-
saving for Brazil. These results could help to reduce the tobacco related disease
burden while agreeing with cost-containment policies.
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OBJECTIVES: To demonstrate Rx data application in relation to comparative effec-
tiveness of inhaled corticosteroids (ICS) through evaluation of the rate of adher-
ence to drug therapy and consumption of rescue medications in respiratory im-
paired patients. METHODS: Participants: A total of 533,382 patients age 18 or older
who filled a prescription for ICS drugs. Setting: More than 12,153 community phar-
macies nationwide. Data were from computerized pharmacy records. Design: The
persistency analysis included prescription data for ICS dispensed during a 4-month
period. Patient prescription activity was followed for 360 days. Patients were mon-
itored for consumption of short acting beta agonist (SABA) medication in combi-
nation with their index ICS for 360 days from their ICS index fill date. An average
SABA consumption in days for each index ICS drug was calculated. RESULTS: Per-
sistence with ICS is generally poor; about 60% to 78% of patients drop off therapy
within the first 30 days of therapy. Fluticasone/salmeterol (F/S) combination shows
the best persistence and budesonide the worst persistence. Children were more
persistent with mometasone whereas patients 19-60 and 60were more persistent
with F/S. Budesonide and triamcinolone had the worst persistence with all age
groups. The same results were seen in patients with multiple co-morbidities. Per-
sistency with ICS across different co-morbid condition was consistent. On average
67% to 91% of ICS users took a SABA concomitantly. Budesonide (N69,432) pa-
tients on average used fewer days of SABA therapy (higher control), whereas
budesonide/formeterol combination (N25,763) patients used more days of SABA
therapy (lower control). CONCLUSIONS: Rx data can be used to compare effective-
ness of drugs in a class across different population segments. Our analysis showed
that different ICSs have different effectiveness, as indicated by the rate of adher-
ence to therapy and use of rescue medication, in different individuals.
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OBJECTIVES: To model the outcomes associated with alpha-1-antitrypsin defi-
ciency (AATD) related emphysema, an orphan disease, through the use of a Markov
cohort model. METHODS: A simulated cohort of 773 patients (the number pre-
dicted patients in the UK) were transitioned between seven health states: mild,
moderate, severe, very severe, lung transplantation, post lung transplantation and
death, according to transition probabilities calculated from pooled randomised
controlled trials. Computed tomography (CT) is accepted to be a more sensitive and
correct measure of progression of disease in AATD-related emphysema, whereas
FEV1 is a more recognised measure of lung function for clinical management of
pulmonary disorders. Thus to model disease progression, CT decline from the
randomised trials was converted to FEV1 decline through two different mapping
algorithms, and transition probabilities calculated accordingly. Health-Related
Quality of Life decreases as disease progresses, with utility values taken from the
literature. At the stage where FEV1 % predicted fell below an eligible threshold,
patients underwent lung transplantation. A predefined limitation on the number of
lungs available reflected the competition for lung transplantation in the healthcare
system. The model outputs include Life Years, QALYs, Lung transplantations, and
disease specific mortality. All values were discounted at 3.5%. RESULTS: AAT re-
placement therapy resulted in an increase of 0.32 life years (6.93 vs. 6.61), with an
estimated gain of 0.28 QALYs per patient (4.64 vs. 4.27) over best supportive care.
For a cohort of 773 patients over a lifetime horizon, 19 AAT deficiency deaths and 6
lung transplantations were avoided when patients were treated with AAT com-
pared to best standard care. CONCLUSIONS: Treatment with AAT slows decline in
lung function and delays death associated with AATD. By slowing lung function
decline, patients experience improved health related quality of life, while fewer
lung transplantations are required, increasing the number of donor organs avail-
able for use in other diseases.
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OBJECTIVES: To assess the effectiveness on treatment adherence of a multifacto-
rial intervention in patients with COPD. METHODS: Design: Randomized Control
Trial (ISRCTN 15106246) Patients: 146 subjects randomly allocated (random blocks
of 4 patients) in two groups (intervention group: IG, control group: CG). Intervention
components: 1) Motivational aspects related with adherence: beliefs-behaviour
about COPD (group and individual interviews); 2) Cognitive aspects: information
about illness; and 3) Skills: inhaling techniques training. Follow-up: 1 year, 5 visits/
group: 1) V0 random allocation, all variables were measured; 2) V0C adherence was
measured; 3) V1-V2 (3-6 moths after start/intervention) adherence and variable
changes were measured; and 4) V3 (one year after start/intervention) all variables
were measured. Primary Outcome: adherence (doses recount); Secondary Out-
comes: functional status (spirometry), quality of life (Saint George Respiratory
Questionnaire-SGRQ); Independent variables: age, sex, educational level, comor-
bidity, COPD severity stage (SEPAR guidelines), prescribed medication. RESULTS:
Predominace of males (91.8%), mean age 69.01 years (CI95%, 67.58-70.44); low cul-
tural level (78.1%), 32.2% current smokers (29.36 cigarettes/day [CI 95%, 26.03-32.7])
overweight (Body Mass Index 30.78 kg/m2 [CI 95%, 28.78-32.78]), 81.2% mild-mod-
erate severity stage, predominance of obstructive respiratory pattern; FEV1
(mean)68.76% (CI 95%, 65.23-72.29), 0.87 exacerbations/year [CI95%, 0.68-1.06].
Pharmacological treatment: inhaled-anticholinergic (77.4%); inhaled-beta2-ad-
renérgic (80.1%); inhaled-corticosteroids (70.5%); xantins (8.2%); oxygen therapy
(4.8%); oral-corticosteroids (0.7%); mucolytics (11.6%). All these measurements
were similar in both groups. Adherence was 41% (41.2CG/40.8IG). 93 patients
(63.7%) completed follow-up. Adherence in follow-up V161.8% (58.9CG/65.2IG),
V266.3% (63.2CG/71.1IG), V356.8% (43.1CG/72.7IG). Significative differences be-
tween study groups (p0.004). NNT for intervention:6,8 .Multivariate analysis (Ad-
herence): (specificity  87.5%, sensibility  60.4%): intervention [OR6.066 (IC95%,
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